All In Biotech

Drug Trial Radar · NCT06769659

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

A Single-center, Double-blind, Placebo-controlled Crossover Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Mar 11, 2025

Primary completion

Aug 17, 2026

Study completion Sep 23, 2026

Sponsor

Lead sponsor
NeuroPro Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.

Conditions

  • Epilepsy, Generalized
  • Epilepsy, Absence

Interventions

  • NPT 2042Drug

    NPT 2042 is a new drug being developed as an anti-seizure treatment

  • PlaceboOther

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean and median across subjects of the within subject difference in percent change from treatment period baseline of the frequency of absence seizuresTime frame: Up to 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials, Inc. (CTI)

    Little Rock, Arkansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.